Elinzanetant - Wikipedia
Elinzanetant (developmental code names BAY-3427080 GSK-1144814, NT-814) is an orally active small-molecule neurokinin/tachykinin NK 1 receptor and NK 3 receptor antagonist which …
Elinzanetant significantly reduces frequency and severity of …
2024年5月16日 · Elinzanetant is a first dual neurokinin-1,3 (NK-1,3) receptor antagonist, in late-stage clinical development for the non-hormonal treatment of moderate to severe VMS …
Bayer submits New Drug Application to U.S. FDA for elinzanetant …
2024年8月1日 · Elinzanetant is the first dual neurokinin-1 and 3 (NK-1 and 3) receptor antagonist, in late-stage clinical development for the non-hormonal treatment of moderate-to-severe VMS …
Elinzanetant VMS update: As Positive Results Pile Up, Bayer …
2025年1月15日 · According to the recently released results from OASIS 4, elinzanetant significantly reduced the frequency and severity of moderate to severe VMS in women …
Elinzanetant Found Safe, Effective for VMS Linked to Breast …
2025年1月20日 · Elinzanetant achieved a statistically significant reduction in the frequency of moderate to severe VMS from baseline to weeks 4 and 12 compared to placebo. Notably, the …
Positive topline results from Phase III long-term study OASIS 3 ... - Bayer
2024年3月19日 · Elinzanetant is the first dual neurokinin-1,3 (NK-1,3) receptor antagonist, in late-stage clinical development for the non-hormonal treatment of moderate to severe VMS …
Bayer files first application of menopause drug elinzanetant
6 天之前 · Bayer has filed for approval in the US for elinzanetant as a non-hormonal treatment for menopausal symptoms such as hot flushes, with a rival therapy from Astellas in its sights.
Elinzanetant - Drugs.com
Elinzanetant is the first dual neurokinin-1 and 3 (NK-1 and 3) receptor antagonist, in late-stage clinical development for the non-hormonal treatment of moderate to severe VMS associated …
Positive topline results of the Phase… | Speaking of Women’s Health
2024年3月27日 · Elinzanetant is the first dual neurokinin (NK-1,3) receptor antagonist, in late-stage clinical development for the non-hormonal treatment of moderate to severe VMS …
Elinzanetant May Treat Hot Flashes Caused by Breast Cancer …
2025年1月15日 · Elinzanetant, a drug targeting estrogen-sensitive neurons in the brain, significantly reduced the frequency and severity of hot flashes in women with breast cancer …